Xilio Therapeutics Inc [XLO] stock is trading at $0.73, up 3.42%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The XLO shares have gain 5.99% over the last week, with a monthly amount glided 4.93%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Xilio Therapeutics Inc [NASDAQ: XLO] stock has seen the most recent analyst activity on December 21, 2022, when Chardan Capital Markets initiated its Buy rating and assigned the stock a price target of $7. Previously, H.C. Wainwright started tracking the stock with Buy rating on January 10, 2022, and set its price target to $36. On November 16, 2021, Raymond James initiated with a Outperform rating and assigned a price target of $31 on the stock. Morgan Stanley started tracking the stock assigning a Overweight rating and suggested a price target of $32 on November 16, 2021. Guggenheim initiated its recommendation with a Buy and recommended $40 as its price target on November 16, 2021.
Xilio Therapeutics Inc [XLO] stock has fluctuated between $0.62 and $1.70 over the past year. Currently, Wall Street analysts expect the stock to reach $7 within the next 12 months. Xilio Therapeutics Inc [NASDAQ: XLO] shares were valued at $0.73 at the most recent close of the market. An investor can expect a potential return of 858.9% based on the average XLO price forecast.
Analyzing the XLO fundamentals
Gross Profit Margin for this corporation currently stands at 0.59% with Operating Profit Margin at -6.14%, Pretax Profit Margin comes in at -4.43%, and Net Profit Margin reading is -4.43%. To continue investigating profitability, this company’s Return on Assets is posted at -0.4, Equity is -1.99 and Total Capital is -1.01. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.73.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.7166 points at the first support level, and at 0.6987 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.7478, and for the 2nd resistance point, it is at 0.7611.
Ratios To Look Out For
For context, Xilio Therapeutics Inc’s Current Ratio is 1.96. Also, the Quick Ratio is 1.96, while the Cash Ratio stands at 1.87. Considering the valuation of this stock, the price to sales ratio is 4.10, the price to book ratio is 3.55.
Transactions by insiders
Recent insider trading involved Shannon James Samuel, Director, that happened on Jun 16 ’25 when 45000.0 shares were purchased. Director, Shannon James Samuel completed a deal on Jun 17 ’25 to buy 25000.0 shares. Meanwhile, PRESIDENT AND CEO Russo Rene bought 36289.0 shares on Jun 16 ’25.
